Dashboard
Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 2.80%
- Poor long term growth as Net Sales has grown by an annual rate of 0.19% over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -2.22
Flat results in Sep 26
Stock is technically in a Mildly Bearish range
With ROE of 1.9, it has a Expensive valuation with a 1 Price to Book Value
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
INR 199 Cr (Micro Cap)
55.00
40
0.00%
-0.31
1.90%
1.05
Total Returns (Price + Dividend) 
Brooks Lab. for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News

Brooks Laboratories Downgraded to Strong Sell Amidst Expensive Valuation and Weak Financials
Brooks Laboratories Ltd has been downgraded from a Sell to a Strong Sell rating by MarketsMojo as of 13 Nov 2026, reflecting a deteriorating outlook driven primarily by an expensive valuation, stagnant financial trends, weak quality metrics, and unfavourable technical indicators. The pharmaceutical company’s micro-cap status and recent quarterly results have further compounded investor concerns, signalling caution for stakeholders.
Read More
Brooks Laboratories Ltd is Rated Strong Sell
Brooks Laboratories Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 14 August 2026. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 28 October 2026, providing investors with the latest insights into the company’s performance and outlook.
Read More
Brooks Laboratories Ltd is Rated Strong Sell
Brooks Laboratories Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 14 August 2026, reflecting a reassessment of the stock’s outlook. However, the analysis and financial metrics discussed below are based on the company’s current position as of 17 October 2026, providing investors with the latest insights into its performance and prospects.
Read More Announcements 
Announcement under Regulation 30 (LODR)-Credit Rating
12-Nov-2026 | Source : BSEIntimation of upgrade in Credit Rating
Announcement under Regulation 30 (LODR)-Newspaper Publication
09-Nov-2026 | Source : BSEBrooks Laboratories Limited has informed the exchange about copy of Newspaper Publication.
Board Meeting Outcome for Board Meeting Outcome For Financial Results For The Quarter And Half Year Ended September 30 2026
07-Nov-2026 | Source : BSEFinancial Results for the quarter and half year ended September 30 2026
Corporate Actions 
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
Brooks Laboratories Ltd has announced 1:16 rights issue, ex-date: 28 Jul 23
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2026
Shareholding Compare (%holding) 
Promoters
None
Held by 1 Schemes (9.9%)
Held by 2 FIIs (0.04%)
Atul Ranchal (19.24%)
Quant Mutual Fund - Quant Business Cycle Fund (9.9%)
30.82%
Quarterly Results Snapshot (Consolidated) - Sep'26 - QoQ
QoQ Growth in quarter ended Sep 2026 is -16.16% vs 13.61% in Jun 2026
QoQ Growth in quarter ended Sep 2026 is 3,877.09% vs -217.76% in Jun 2026
Half Yearly Results Snapshot (Consolidated) - Sep'25
Growth in half year ended Sep 2025 is 26.41% vs -3.22% in Sep 2024
Growth in half year ended Sep 2025 is 375.24% vs -4.42% in Sep 2024
Nine Monthly Results Snapshot (Consolidated) - Dec'25
YoY Growth in nine months ended Dec 2025 is 10.60% vs -4.08% in Dec 2024
YoY Growth in nine months ended Dec 2025 is 370.98% vs 14.81% in Dec 2024
Annual Results Snapshot (Consolidated) - Mar'26
YoY Growth in year ended Mar 2026 is 3.85% vs 3.86% in Mar 2025
YoY Growth in year ended Mar 2026 is 346.54% vs 49.11% in Mar 2025